To analyze both antifibrotic and anti-inflammatory properties exerted by 17-DMAG, we used the traditional outcome measures assessing dermal thickness, collagen content, activation of fibroblasts and of TGF-β pathway, including expression of pSmad3, TβRI, and TβRII, as well as markers of local and systemic inflammation, including selected cytokines and chemokines with established proinflammatory roles in the pathogenesis of SSc [1,2,7,29]. The gene discussed is TGFBR1; the disease is systemic sclerosis.